It would be interesting to see a total breakdown of the expenditures of the various trial on AD over that 30+ year.
Here is a pretty good summary. Anyone on upper management in the FDA should have been asked to explain this use of funds over a very long period of time. Poorly managed is being generous.
A critical point here is , at the outset AVXL would have had to swim upstream against this very large organization. Today we look ack and may judge ... it's obvious....but not then.